This is a NASA image. It's not a galaxy or a Saturnian moon. It's a breast mammogram made with the same tools used to enhance the images taken by their Earth observation satellites. And it helps doctors detecting cancer earlier. More »
Memey treachery! Viral video legend Isiah Mustafa appears in a new video, where he not-so-subtly alludes to the Windows Phone 7 launch, and an apparent ad campaign starring himself. I always thought advertising was a loyal business—how disillusioning. More »
The feature to use GPS coordinates inside geotagged photos as a waypoint to navigate to is an obvious one, but actually a pretty clever use if you think about it. Good job, TomTom. More »
Tekmira Pharmaceuticals Corporation, a leader in RNA interference (RNAi) therapeutics, announced today that, together with collaborators at The University of Texas Medical Branch, it has been awarded a new United States National Institutes of Health (NIH) grant to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections using Tekmira's lipid nanoparticle (LNP) delivery technology.
Die Deutsche Forschungsgemeinschaft (DFG) hat Dr. Sabine Wurmehl in ihr renommiertes Emmy-Noether-Programm zur Foerderung des wissenschaftlichen Nachwuchses aufgenommen. Der inhaltliche Schwerpunkt liegt in Materialien fuer die Spintronik.
Aridion, P2i's revolutionary liquid repellent nano-coating, is now providing unbeatable protection against corrosion damage for more than two million hearing aid users worldwide.
The FlexTech Alliance, focused on developing the supply chain for displays and flexible, printed electronics, today announced that it has awarded Corning Incorporated a grant to develop commercially viable methods for continuous printed electronic manufacturing on flexible glass substrates. The general substrate design and process methods identified will be applicable to a wide range of applications including sensors, energy harvesting and storage, displays, and solid state lighting.
$127.5M state-of-the-art facility to include Computer Chip Commercialization Center that will further expand New York State's world-class nanotechnology initiative.
A versatile formula describes the energetic conditions needed to transport molecules laterally on surfaces.
DuPont Kabushiki Kaisha and Fujipream Corporation have successfully developed a new thin crystalline silicon (c-Si) glass-glass photovoltaic module that is 25 percent lighter in weight (excluding the frame) compared with traditional c-Si modules using standard solar grade front glass.
The National Industrial Chemicals Notification and Assessment Scheme (NICNAS) is introducing new administrative processes for the notification and assessment of industrial nanomaterials that are considered to be New Chemicals under Part 3 (Notification and Assessment of Industrial Chemicals) of the Industrial Chemicals Notification and Assessment Act 1989 (the Act).
The Nanomaterialstore is pleased to announce that they have released their first upconversion lanthanide nanocrystal product. This complements their range of UV downconversion nanocrystals, and represents an expansion of their range of biomedical research compounds.
Extracting drinking water from the sea to prepare for a world parched by climate change, and re-imagining aeroplane and ship hull designs for the best fuel efficiency, are two of the visionary applications of a new GBP2.4 million research project announced today at the University of Strathclyde in Glasgow, Scotland.
The funds will support the NU Center of Cancer Nanotechnology Excellence, a collaborative venture between NU's International Institute for Nanotechnology and the Chicago-based Robert H. Lurie Comprehensive Cancer Center.
Bayer MaterialScience is working on the development of polyurethane nanofoams that could lead to a quantum leap in thermal insulation performance several years down the road.
Owlstone, Inc. has won the coveted and prestigious Cambridge Phenomenon Award 2010 at the 50th Anniversary of The Cambridge Phenomenon Conference 'Future Starts Here'.
Balaji Sitharaman, Ph.D., Assistant Professor of Biomedical Engineering at Stony Brook University, is a 2010 recipient of the National Institutes of Health (NIH) Director's New Innovator Award. Only a select group of early-career biomedical researchers nationwide receive this award, which includes a 5-year $1.5 million grant.
As the FDA debates what they should do, Barbara Evans at the University of Houston Law School and Amy L. McGuire of the Center for Medical Ethics and Health Policy at Baylor College of Medicine in Houston, also includes, Canadian legal expert Timothy Caulfield and Wylie Burke, M.D., of the University of Washington School of Medicine post some guidelines for regulation of DTCG/LDT genetic testing.
I love this sort of handicapping.
You have absolutely brilliant people posing ideas for regulations. I have read a ton. There are those from industry insiders, Ones from industry "Advisors", Ones from politicians who receive funding from industry, Ones from academic centers that do LDT testing. Ones from bioethicists...
But I have paid attention to the mixed group that includes pragmatist Wylie Burke and Barb Evans
In an article I just read from Science published October 8th. They propose rules for DTCG, but I am certain they also would work for LDT.
What they propose is a "sliding scale of potential harm"
Which is sort of what I had been saying for years, which perhaps is why it rings true.
If this is for earwax type, let it go to market, if it is for medically related decision making, probably needs some regulation.
The proponents for a wild west DTCG (WWDTCG), which BTW includes a "registry" say
"Well, there is no proof of harm or risk"
I say, well, this is not about psychologic risk.
Instead, it is about medically actionable risk.
I say this because recently, Kif6 testing has fallen into question, despite a company promoting these tests to physicians.
The test is marketed as a "Statin response" genetic test.
Can you imagine how many people were started on statins? Well, 250,000 tests had been ordered. Even if 10% were started it would be nearly as many people as DCTG 23andMe have tested.
The real problem here: Pharmacogenomics tests are not something you hide, you ask your doctor to use these results. Unless you are a doctor, you can't use these results to dose medications.......
That is a real risk. Despite what WWDTCG proponents say.
Another risk, BRCA testing. I cringe at the thought that a doctor would use 23andMe results and only those results to infer carrier status of BRCA 1/2
The same goes for CF carrier status.
These DTCG medical tests aren't recreational. These companies added these tests because NO ONE wanted to pay hundreds, hell thousands of dollars to find out these risks.....
In a business decision, they fell short of looking at the medical risks.
So yes, a sliding scale of regulation is likely coming. But not because of Wylie, because of the FDA.
It is obvious. Again, medical testing will be regulated as medical. Ear Wax as ear wax. Will LDT be forced to go through pre-market review? Probably not if they can only be ordered by licensed professionals.....
It's not a form a rent seeking, it is a form of guidance and protection for consumers. That's why physicians are licensed and malpractice covered.
Yes, yes. Someday everyone will have these genomes done and everyone will be educated enough to know what they mean. And all humans will have medical education and we can replace the oligarchy of physicians and the tyrannical healthcare system once and for all........
But until that day, we will have to rely on trained professionals who don't have their retirements tied to their company's new genetic test......
The Sherpa Says: Handicapping of the FDA by the Sherpa. If it has any medical utility it will be regulated as either Class II or III. If only ordered via physician it will more likely be Class II. If not, will need Class III.
For some, medical marijuana offers pain relief Monroe Evening News The law, the men said, has meant freedom from man-made drugs. "It helps," JoeJoe said. "It doesn't get rid of the pain, it just relieves it. ... |
HARVARD MEDICAL SCHOOL ADVISER Early breast cancer treatment Detroit Free Press This can be a special burden for women who live far from a medical center. The newest thinking is that a shorter course of radiation treatment may be just ... |
